Navigation Links
Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimer's Disease in MedPredict Report
Date:6/17/2008

SCOTTSDALE, Ariz., June 17 /PRNewswire/ -- MedPredict has published a new report designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area. The report, entitled "Thought Leader Insight & Analysis: Alzheimer's Disease," is based on in-depth interviews conducted with a panel of physician thought leaders actively involved in ongoing research.

"There is some real progress being made in development of diagnostics and treatments for Alzheimer's disease," said Dr. Jeffrey Berk, the primary author of this report. "Today's announcement by Wyeth and Elan revealing clinically meaningful results in their Phase II trial of bapineuzumab underscores that progress. Our Thought Leader Panel is excited about the potential for bapineuzumab, and this report provides their interpretation of the trial results and how they might impact ongoing research."

Each panelist offers his perspective on those agents and mechanisms that have the strongest data supporting them, and comments on those where the excitement extends beyond the clinical evidence. These include ARBs, acetylcholinesterase (butyrylcholinesterase) inhibitors, NMDA, M1, 5-HT, alpha-7 nicotinic acetylcholine agonists, active and passive immunotherapy, gamma-secretase and beta-secretase inhibitors, insulin related mechanisms (IDE, RAGE), anti-TNF and more.

With regard to diagnostics, "We expect demand for diagnostics is going to skyrocket in concert with approvals of agents that alter the course of the disease," continued Dr. Berk. "Our panelists are most excited about amyloid imaging using a tracer chemical called PIB."

Companies mentioned in this report: GE Healthcare, Avid, Bayer Schering, Siemens, C2N Diagnostics, Satoris, Novartis, Forest, Merz, Lundbeck, Daiichi Sankyo, Medivation, Abbott, AstraZeneca, Targacept, Roche, Memory, EnVivo, Wyeth, Epix, GlaxoSmithKline, Merck, Takeda, Sanofi-Aventis, Bristol Myers Squibb, Boehringer Ingelheim, Baxter, Lilly, Intellect Neurosciences, Elan, Myriad, AC Immune, Genentech, Affiris, TransTec, Pfizer, TorreyPines, Transition Therapeutics, Neurochem.

The full report can be purchased by contacting MedPredict at http://www.medpredict.com.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DuPont Leaders Brief Investors on Agriculture Businesses
2. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
3. Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry
4. KGI and Smith College Establish Leadership Forum for Women in Bioscience
5. RF Pain Management Industry Leaders Cotop International and NeuroTherm, Inc. Agree to Merge
6. Campbell Alliance Managed Markets Practice to Take Leadership Role at CBIs Formulary and Reimbursement Conference
7. Assay Designs(TM) Announces Additions to the Leadership Team
8. Deloitte Leadership Offers Crucial Convergence Considerations for Life Sciences Companies
9. 2007 Global Survey Identifies Characteristics of Supply Chain Leaders
10. Dr. Dinesh Verma to be honored with Presidents Leadership Award at Edwin A. Stevens Society Gala
11. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and ... clinical trial team. , Using the CONSULT module, patients and physicians can schedule a ...
(Date:6/27/2016)... Chapel Hill, N.C. (PRWEB) , ... June 27, ... ... of U.S. commercial operations for Amgen, will join the faculty of the ... will serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
Breaking Biology News(10 mins):